Benefits of rilpivirine for liver stiffness in HIV/HCV-coinfected patients

Rivero, 2007, Liver toxicity induced by non-nucleoside reverse transcriptase inhibitors, J Antimicrob Chemother, 59, 342, 10.1093/jac/dkl524 Documento de Consenso de GeSIDA/Plan Nacional sobre el SIDA respecto al tratamiento antirretroviral en adultos infectados por el VIH. https://gesida-seimc.org/wp-content/uploads/2020/07/TAR_GUIA_GESIDA_2020_COMPLETA_Julio.pdf. EACS Guidelines v 10.1, October 2020. https://www.eacsociety.org/files/guidelines-10.1_finaljan2021_1.pdf. DHHS Guidelines, January 2020. https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv/whats-new-guidelines. Lee, 2015, Pathobiology of liver fibrosis: a translational success story, Gut, 64, 830, 10.1136/gutjnl-2014-306842 Martí-Rodrigo, 2019, Rilpivirine attenuates liver fibrosis through selective STAT1-mediated apoptosis in hepatic stellate cells, Gut 2009 Fedchuk, 2014, Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease, Aliment Pharmacol Ther, 40, 1209, 10.1111/apt.12963 Schwabl, 2017, Interferon-free regimens improve portal hypertension and histological necroinflammation in HIV/HCV patients with advanced liver disease, Aliment Pharmacol Ther, 45, 139, 10.1111/apt.13844 Rial-Crestelo, 2020, Does fibrosis really regress in HIV/hepatitis C virus co-infected patients after treatment with direct antiviral agents?, AIDS, 34, 427, 10.1097/QAD.0000000000002433 Blas-Garcia, 2014, Lack of mitochondrial toxicity of darunavir, raltegravir and rilpivirine in neurons and hepatocytes: a comparison with efavirenz, J Antimicrob Chemother, 69, 2995, 10.1093/jac/dku262 Macías, 2017, Changes in liver steatosis after switching from efavirenz to raltegravir among human immunodeficiency virus-infected patients with nonalcoholic fatty liver disease, Clin Infect Dis, 65, 1012, 10.1093/cid/cix467 Kim, 2014, Assessment of hepatic fibrosis regression by transient elastography in patients with chronic hepatitis B treated with oral antiviral agents, J Korean Med Sci [Internet], 29, 570, 10.3346/jkms.2014.29.4.570 Nelson, 2012, Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the phase III randomized, double-blind ECHO and THRIVE trials, J Antimicrob Chemother, 67, 2020, 10.1093/jac/dks130 Neukam, 2016, Hepatic safety of rilpivirine/emtricitabine/tenofovir disoproxil fumarate fixed-dose single-tablet regimen in HIV-infected patients with active hepatitis C virus infection: the hEPAtic study, PLOS ONE, 11, e0155842, 10.1371/journal.pone.0155842 Thamrongwonglert, 2016, Improvement of lipid profiles when switching from efavirenz to rilpivirine in HIV-infected patients with dyslipidemia, HIV Clin Trials, 17, 12, 10.1080/15284336.2015.1112480 Di Biagio, 2016, Switch from unboosted protease inhibitor to a single-tablet regimen containing rilpivirine improves cholesterol and triglycerides, Int J Antimicrob Agents, 48, 551, 10.1016/j.ijantimicag.2016.07.009 Surgers, 2013, Hepatoxicity of new antiretrovirals: a systematic review, Clin Res Hepatol Gastroenterol, 37, 126, 10.1016/j.clinre.2013.02.008 López Cortés, 2013, Perfil de seguridad de rilpivirina: tolerabilidad general y neuropsiquiátrica, seguridad en pacientes coinfectados con virus de la hepatitis B/virus de la hepatitis C, y perfil lipídico, Enferm Infecc Microbiol Clin, 31, 6, 10.1016/S0213-005X(13)70137-X Wang, 2018, Liver stiffness measurement predicted liver-related events and all-cause mortality: a systematic review and nonlinear dose–response meta-analysis, Hepatol Commun, 2, 467, 10.1002/hep4.1154 Shen, 2019, The prognostic role of liver stiffness in patients with chronic liver disease: a systematic review and dose–response meta-analysis, Hepatol Int, 13, 560, 10.1007/s12072-019-09952-5